Vanguard Group Inc. purchased a new stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 6,315,113 shares of the company’s stock, valued at approximately $4,105,000. Vanguard Group Inc. owned 118.17% of Cartesian Therapeutics at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in Cartesian Therapeutics in the 1st quarter worth about $31,000. Hall Laurie J Trustee bought a new position in shares of Cartesian Therapeutics during the first quarter worth approximately $34,000. BNP Paribas Financial Markets acquired a new stake in shares of Cartesian Therapeutics in the first quarter valued at approximately $38,000. Finally, Delphi Financial Group Inc. bought a new stake in shares of Cartesian Therapeutics in the first quarter valued at approximately $430,000. Institutional investors own 86.95% of the company’s stock.
Insider Activity
In other Cartesian Therapeutics news, Director Timothy A. Springer bought 8,016 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was bought at an average cost of $12.72 per share, with a total value of $101,963.52. Following the completion of the transaction, the director now directly owns 11,509 shares in the company, valued at approximately $146,394.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 61.10% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on Cartesian Therapeutics
Cartesian Therapeutics Stock Performance
Cartesian Therapeutics stock opened at $14.22 on Monday. The firm has a 50 day moving average price of $19.12 and a two-hundred day moving average price of $21.00. Cartesian Therapeutics, Inc. has a 52-week low of $11.66 and a 52-week high of $42.60.
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of ($0.81) by $1.35. The business had revenue of $33.45 million during the quarter, compared to the consensus estimate of $6.00 million. Equities analysts expect that Cartesian Therapeutics, Inc. will post 3.99 earnings per share for the current fiscal year.
Cartesian Therapeutics Company Profile
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
Further Reading
- Five stocks we like better than Cartesian Therapeutics
- What is a SEC Filing?
- This Small Cap Wealth Management Stock Could Provide Big Returns
- 3 Monster Growth Stocks to Buy Now
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How to Find Undervalued Stocks
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.